Industry Sponsored Program

Satellite Symposia Timetable
|
|
Saturday May 11, 2019
|
|
10:50-11:50 | Hall A | Satellite Symposium A
Supported by Novo Nordisk
Alleviating burden and promoting differentiation - the lifeline for β cells: Li Guangwei, China The effect of insulin on weight gain: Huang Qing, China |
![]() |
10:50-11:50 | Hall B | Satellite Symposium B
Supported by MSD
Chairperson: Ning Guang, China Incretin in clinical, now and future: Wang Weiqing, China Incretin and islet function: Peng Yongde, China |
![]() |
10:50-11:50 | Hall C | Satellite Symposium C
Supported by Servier
Chairpersons: Zhu Dalong, China and Wang Weiqing, China The Importance of Glycemic Control: Li Yan, China The Whole Journey Management of T2DM Patients: Su Qing, China |
![]() |
12:00-13:00 | Hall A | Satellite Symposium D
Supported by Eli Lilly
Chairperson: Wang Weiqing, China and Shan Zhongyan, China New GLP-RA weekly formulation, new choice to control T2DM: Li Yan, China Open the new era of diabetes treatment: Li Guangwei, China |
![]() |
12:00-12:30 | Hall B | Satellite Symposium E
Supported by Bayer
Chairperson: Ning Guang, China Improving management of type 2 diabetes: Stimulate insulin or provide beta-cell rest?: Qu Shen, China GUT study: the new insigth the mechanism of acarbose action and benefit: Wang Weiqing, China |
![]() |
12:00-12:30 | Hall B | Satellite Symposium E
Supported by Novartis Galvus Add-on Met, best partner - Clinical significance of VERIFY study from intensive therapy: Qin Guijun, China Galcus Add-on Insulin, perfect complement - New choice of premixed insulin combined with OAD: Peng Yongde, China |
![]() |
14:30-15:30 | Hall A | Satellite Symposium G
Supported by AstraZeneca Chairperson: Wang Weiqing, China Only one pill once a day with 3 meals PPG control: Peng Yongde, China New choice of hypoglycemic strategy: Early use, early protection!: Zou Dajin, China |
![]() |
14:30-15:30 | Hall B | Satellite Symposium H
Supported by Pfizer
Chairpersons: Ning Guang, China Statins Treatment of Type 2 Diabetes Mellitus from the Perspective of Vascular Inflammation: Zou Dajin, China Lipid Management of Type 2 Diabetes Mellitus from the Perspective of ASCVD Risks: Wang Weiqing |
![]() |
14:30-15:30 | Hall C | Satellite Symposium I
Supported by Omron
Chairperson: Ning Guang, China Discuss the development and construction of endocrinology department from the diabetic complications screening of MMC: Wang Weiqing, China Diabetic complications screening improve outcome of type 2 diabetes, from science to practice of MMC: Zhu Dalong, China |
![]() |
Sunday May 12, 2019
|
|
10:50-11:50 | Hall A | Satellite Lunch Symposium J
Supported by Hansoh Pharma
Chairperson: Ning Guang, China Major updates on long-acting GLP-1RA for type 2 diabetes: Li Yan, China |
![]() |
10:50-11:50 | Hall B | Satellite Lunch Symposium K
Supported by Abbott
Chairperson: Ning Guang, China and Wang Weiqing, China Chinese flash glucose monitoring consensus inerpretation: Li Yanbing, China TIR: New index to evaluate short term glucose: Wang Weiqing, China |
![]() |
10:50-11:50 | Hall C| Satellite Lunch Symposium L
Supported by Tide Pharmaceutical
Chairpersons: Liu Wei, China and Wang Weiqing, China Interpretation of the guidelines for the prevention of type 2 diabetes: Su Qing, China |
![]() |
12:00-13:00 | Hall A | Satellite Lunch Symposium M
Supported by NovoNordisk
Chairpersons: Ji Linong, China Precision medicine as general trend of the treatment - Application of GLP -1RA in new typing of diabetes: Shi Yongquan, China |
![]() |
12:00-13:00 | Hall B | Satellite Lunch Symposium N
Supported by CR Double-Crane
Chairpersons: Wang Weiqing, China Combined treatment in time: Liao Lin, China |
![]() |
12:00-13:00 | Hall C | Satellite Lunch Symposium O
Supported by DongBao Diabetes
Chairpersons: Ning Guang, China and Wang Weiqing, China The reasonable application of insulin in China: Guo Xiaohui, China Discussion on Chinese Slow Disease Management Model: Xu Fengmei, China |
![]() |